Objective: Using a recombinant rat leptin antagonist, we investigated the effects of early postnatal leptin disruption on long-term leptin sensitivity and metabolic phenotype. Design: Three groups of 10 newborn female Wistar rats were injected subcutaneously with either saline (control) or leptin antagonist (at 2.5 or 7.5 mg g À1 day À1 ) from postnatal day 2 to day 13. Results: At weaning (day 28), antagonist-treated rats presented similar body weight (BW) compared to control animals. At 3 months of age, there was no significant change in BW, food intake and leptin or insulin levels between groups. Only a disturbed relationship between circulating insulin and glucose levels was observed in antagonist-treated animals. At 4 months of age, treated animals developed a leptin resistance appreciated by the lack of response to a 7-days leptin treatment (1 mg kg À1 day À1 ) in term of decrease in food intake and BW. At 8 months of age, following 3 months of high-energy diet, rlepm7.5 animals presented higher BW gain associated with increased body fatness and striking hyperleptinaemia as compared to control animals. Conclusion: The blockage of leptin action during the critical period of early life in rodents has long-term consequences by altering the capacity to respond to leptin during adulthood, thus predisposing the animals to obesity. These findings clearly demonstrate the physiological importance of the postnatal leptin surge for the optimal onset of the metabolic regulation, at least in rodents, and its implication in the prevention of unfavourable developmental programming.
Introduction
During the last decade, the incidence of obesity has increased at a worrying rate all over the world. 1, 2 The epidemic now also affects young children, critically compromising life expectancy, as it is often associated with a susceptibility to develop a series of diseases later, such as type 2 diabetes, hypertension and cardiovascular dysfunction regrouped as the well-described 'metabolic syndrome'. Recent epidemiological studies and investigations in experimental animal models have brought new insight on the early events in the ontogeny of obesity and have proposed the concept of 'developmental programming'. 3, 4 This concept supports the idea that nutritional and hormonal status during fetal development and early life determine the long-term control of energy metabolism, particularly by programming the future ingestive behaviour and energy expenditure regulation. Developmental programming may be considered as an attempt to match the original experiences during fetal life to the expected future environment. 5 The mechanisms underlying this metabolic programming remain poorly documented. Several recent discoveries indicate that leptin may play a critical role in the establishment of this programming. 6, 7 Leptin is a 16-kDa cytokine synthesized and secreted essentially by adipocytes and also by several ectopic sources such as placenta, 8 mammary gland 9, 10 and stomach 11, 12 and is involved in an impressive list of biological effects. 13 Leptin, through its long isoform receptor, plays a pivotal role on food intake regulation and exerts its actions at the central level in the hypothalamus within a neuronal network integrating a wide range of nervous, nutritional and hormonal signals. 14, 15 In adults, leptin acts primarily to decrease food intake and stimulate energy expenditure. 16 In the newborn, leptin production and effects appear to be differently regulated from that observed in adults. Indeed, independently of fat storage, a leptin surge occurs in the developing rodent during the second week of life. 17, 18 At this stage, leptin regulates metabolic rate and hypothalamic neuropeptides expression, but not food intake. [19] [20] [21] These observations could be, at least partially, explained by the kinetic in the development of neuronal hypothalamic network, which begins in rodents only after birth (day 6) to be achieved at the end of the second postnatal week. 22 During that temporal window, neuronal projections are developing to interconnect the different hypothalamic nuclei responsible for food intake regulation, and leptin appears to play a crucial role in this phenomenon. 22 Developmental role of leptin seems to be restricted to this critical postnatal period in rodents and it has been shown, in the genetically leptin-deficient ob/ob mice, that the metabolic phenotype can be rescued by leptin supplementation during the early postnatal period. 23, 24 Leptin also appears to play a crucial role in the establishment of the phenotype observed after intrauterine growth retardation, 25, 26 and it has been recently demonstrated that the postnatal treatment of intrauterine growth retardated pups, with recombinant leptin from P3 to P13 reversed developmental programming and normalized, during adult life, metabolic pattern, adiposity and body weight (BW).
27,28
We have recently developed specific leptin muteins acting as competitive antagonists that bind to the leptin receptor with an affinity identical to non-mutated leptin, but completely devoided of agonistic activity. 29, 30 Our aim in this study was, by using these reagents, to assess whether the postnatal leptin surge is critical for the normal development of the newborn and to determine the long-term consequences of its disruption on the adult metabolic pattern. We demonstrated that specific leptin blockage during early life in female rats results in a permanent leptin resistance associated with increased susceptibility to diet-induced obesity.
Methods

Animals
The following animal protocol was approved by the Animal Ethics Committee (Comité Régional d'Ethique sur l'Expéri-mentation Animale Ile-de-France Sud). Gestationally timed pregnant Wistar rats from our breeding stock, were housed individually and allowed free access to water and food. Animals were housed under constant conditions of ambient temperature (20-22 1C) , hygrometry (around 50%) and light (12:12 h light/ dark cycle from 07:00 to 19:00 hours) and fed with a standard chow diet. Two days after delivery (birth ¼ day 0), 30 newborn female pups were weighed, cross fostered and placed under four dams with equalized litter size (eight pups per dam after completing with two additional untreated pups from our breeding) until weaning at day 28.
Neonatal treatment
Rat leptin antagonist (L39A/D40A/F41A) was prepared as previously described. 29 Pups of each litter were randomly assigned into three groups of 10 animals: control (NaCl); rlepm2.5 (leptin antagonist: 2.5 mg g À1 day
À1
); rlepm7.5 (7.5 mg g À1 day
). Pups were weighed and subcutaneously injected between 17:00 and 18:00 hours from day 2 to day 13 with either NaCl or leptin antagonist solutions. Special syringes (0.3 mlU-100 insulin, 29G, Terumo, France) were used to minimize pain with a maximal volume injection of 50 ml. Weight was recorded daily until weaning.
Postweaning studies
After weaning, rats were housed in individual cages and followed for BW and food intake every 3 days. Food intake was assessed between 17:00 and 18:00 hours by measuring the food consumed by weighing the rat chow at the start and end of the 72-h period.
At 3 months of age, blood samples were collected from the retro-orbital plexus. After overnight fasting, rats were briefly anesthesized by isofluorane inhalation to allow the sampling by using heparinized capillaries and collection tubes. After 10 min centrifugation at 4000 g, plasma samples were aliquoted and stored at À80 1C until subsequent hormonal assays. Immediately after placing a drop of blood on a test strip, glycaemia was measured by using a glucometer (OneTouch UltraSmart, LifeScan, Issy Les Moulineaux, France).
At 4 months, rats were submitted to a 7-day leptin challenge to test their ability to respond to leptin in term of food intake and decrease in BW. For that purpose, one-half of the animals of each group (control, rlepm2.5 and rlepm7.5) received daily intraperitoneal injection of NaCl solution and the other half was treated during the 7 days with rat recombinant leptin (1 mg kg À1 ) prepared by us as previously described. 29 Food intake and BW measurements were performed daily between 17:00 and 18:00 hours from 2 days before the beginning of the injection period until 3 days after the end of the treatment. At 5 months of age, rats that received only NaCl during leptin challenge, were placed on a high-energy diet, as described below, for 3 months and recorded weekly for BW during the first two months of diet.
At 8 months, animals were killed by decapitation. Blood samples were collected for leptin and insulin radioimmunoassays. Total abdominal fat was dissected and weighted.
High-energy diet
After few weeks of acclimatization, 5-month-old animals had free access to a cafeteria-style diet as described by Holemans et al., 31 which consists in a semisolid diet containing 33% ground commercial rat chow, 33% full-fat, sweetened condensed milk (Nestlé), 7% sucrose and 27% water.
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Hormone assays
Plasma leptin levels were measured by specific RIA commercial kit (Linco Research, St Charles, MO, USA). The limit of sensitivity was 0.5 ng ml
À1
. The intra assay variation was 6.3% in a concentration range between 0.8 and 2.5 ng ml À1 (n ¼ 27) for assays at 3 months and between 2.2 and 22.2 ng ml À1 for measurements at 8 months (n ¼ 15).
Serum insulin levels were measured using Rat Insulin RIA kit (Linco Research). The limit of detection was 0.1 ng ml
. The intra assay variation was 3.2%. Range of values was comprised between 0.3 and 3.2 ng ml À1 at 3 months (n ¼ 22) and between 0.5 and 2.5 ng ml À1 at 8 months (n ¼ 15).
Statistical analysis
All results were analysed using the ANOVA analysis followed by post hoc, Student's, Newman-Keuls or Bonferroni tests as appropriate. Linear regression analyses were used to determine relationships between glycaemia and insulinaemia at 3 months of age. For all analyses, the level of significance was set at Po0.05. All values are expressed as mean ± s.e.m.
Results
Effect of neonatal leptin antagonist treatment on postnatal growth Figure 1a followed the calculations used by Vickers et al. 28 to represent changes in BW. BW change was calculated as the relative variation between daily registered weight and initial weight at day 2 for each animal reported to a mean daily measurement for control group. The results indicated that neonatal leptin antagonist treatment resulted in a transient reduction in rat BW gain in the rlepm7.5 group during the period of injection from day 2 to day 13 (Po0.05 for effect of the treatment). No significant change in BW gain was observed in rlepm2.5 group (mean relative BW change during the treatment period for rlepm2.5: 3.32 ± 1.39%, not significant). At the end of the treatment, rlepm7.5 BW gain returned to control levels, and BW of rats maintained on a standard chow during the two further months of observations was similar ( Figure 1b) .
Metabolic phenotype at 3 months of age
Food intake measurements performed from weaning until the age of 3 months were similar between groups (data not Postnatal leptin blockage promotes obesity L Attig et al shown), and leptin antagonist-treated rats presented, at 3 months of age, similar BW as control animals (Table 1) . Blood samples taken at this stage indicated no statistically significant differences between groups for glucose, leptin and insulin plasma levels. However, when glucose and insulin levels were considered for each animal, we observed that the leptin antagonist treatment altered the correlation between insulinaemia and glycaemia. Indeed, linear regression analysis indicated that these two parameters were, as expected, negatively correlated (r ¼ À0.93, n ¼ 6, Po0.01) in control animals. This relationship was attenuated in rlepm2.5 rats (r ¼ À0.7, n ¼ 7, not significant) and completely lost in rlepm7.5 rats (r ¼ À0.13, n ¼ 8, not significant). 
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Response to leptin challenge at 4 months of age As shown in Figure 2a , leptin injections strongly reduced food intake in control animals. In contrast, neonatally leptin antagonist-treated animals showed a significant altered leptin response (Po0.01 for leptin effect and Po0.05 for neonatal treatment Â leptin effect). Furthermore, leptin injections in control animals (top panel) induced a significant reduction of food intake beginning from the second day of treatment. Maximal leptin effect occurred at day 7 with a 26.2% decrease of food intake (mean daily food intake at day 7 for NaCl rats was 17.0±1.0 vs 12.5±0.88 g for leptin treated animals). Animals treated with the low dose of leptin antagonist (middle panel) showed a partial leptin resistance on the overall period of treatment, as leptin effect on food intake began only at the end of the injection period for days 6 and 7 (Po0.001). In rlepm7.5 group (lower panel), leptin effect on food intake was completely abolished. The decrease of food intake resulted in loss of BW in control animals as shown in Figure 2b (Po0.0001 on BW and Po0.0001 for neonatal treatment Â leptin effect). The animals presented a significant BW loss beginning from the third day of treatment and lasting even after the end of the injection period (maximal decrease of BW of 4.28±0.83% at day 10 in leptin-injected animals vs 0.21 ± 0.53% in NaCl-injected animals). In contrast, leptin response in term of BW loss was altered in antagonist-treated animals. In the rlepm2.5 group, leptin challenge induced only a slight decrease of BW, observed at the end of the treatment period, from day 7 to day 9 (maximal decrease of BW of 1.85±0.32% at day 9 in leptin-injected animals vs 0.08±0.47% in NaCl-injected animals). The rlepm7.5 group presented a complete loss of leptin response and no significant change in BW was observed.
Response to high-energy diet Figure 3 shows BW gain evolution for rats submitted to a high-energy diet during 3 months. Only animals treated with NaCl at 4 months of age were submitted to the diet to avoid eventual residual effects of the leptin challenge. As shown in this figure, after 9 weeks of high-energy diet, no significant change in BW gain, compared to control, was observed in rlepm2.5 rats. In contrast, rlepm7.5 group presented a significant (Po0.05) higher BW gain compared to control group (49.4 ± 5.0 vs 32.9 ± 4.5%).
At the end of the diet period, antagonist-treated rats were slightly heavier than control animals with a mean BW of 385.4 ± 20.6 g for rlepm7.5 rats compared to 356.6 ± 33.17 g for control group. The higher BW observed in rlepm7.5 rats resulted in an increased abdominal fat content (39±4.4 g for rlepm7.5 group vs 29.5 ± 4.4 g) which was marginally significantly different from control group (P ¼ 0.053) when expressed as relative adiposity, which takes account of total BW (Figures 4a and b) . The increased body fatness in antagonist-treated animals was associated with a more than threefold increase in plasma leptin levels (14.4 ± 3.1 ng ml À1 for rlepm7.5 rats compared to 4.2 ± 0.75 ng ml À1 in control group, Po0.05) without any change in insulin levels ( Figures  4c and d) .
Discussion
This study demonstrates that the blockage of leptin action, during a critical window of early postnatal life, induced in normal newborn female rats permanent defects in their adult metabolic regulation. This study was performed in female rats and it also remains to analyse the effect in male rats to document whether sex-related differences in leptin programming exist. The leptin disruption from day 2 to day 13 by using a specific leptin antagonist led to a long-term leptin resistance evidenced, at 4 months of age, by the loss of the ability of the treated animals to respond to leptin in terms of reduction of food intake and BW. Moreover, treated animals presented higher susceptibility to diet-induced obesity, as shown by a higher BW gain when submitted to a high-energy diet, associated with increased adiposity and leptinaemia. Interestingly, the susceptibility to obese phenotype was revealed after a metabolic transition, whereas the rats were transferred from a normocaloric diet to a hyper caloric and palatable diet. This observation is reminiscent to what is usually observed in the case of developmental programming that Figure 3 Diet-induced weight gain of rats submitted to a high-energy diet at 5 months of age. Only the animals which have been used as control (NaCl injected animals, n ¼ 5 per group) were submitted to the diet beginning at 5 months of age and lasting during 12 weeks. Body weight was recorded weekly during the first 9 weeks. Body weight change was expressed as percent of body weight gain at each week, reported to the body weight measured before starting the experiment.
Postnatal leptin blockage promotes obesity L Attig et al results from a mismatch between prenatal undernutrition and postnatal overnutrition. 32 In female pups born with intrauterine growth retardation, exposure to a high-fat diet after weaning is associated with hyperphagia, higher weight gain and body fat, compared to control offspring. 27 In human, epidemiological evidences also indicate that low-birth weight resulting from fetal undernutrition is associated with an increased risk to develop metabolic syndrome, especially on positive energy balance. 33, 34 The original approach used in this study was based on the use of leptin mutein (L39A/D40A/F41A) acting as a competitive antagonist. 29, 30 The in vivo antagonistic effects of this leptin mutein have been already validated by several groups by using intracerebroventricular administrations. 35, 36 The antagonistic activity occurs at relatively high molar ratio between leptin and leptin mutein. However, even if the dose used was relatively high, it was not associated with aversive effects. The slight decrease in BW gain observed when the high dose of leptin antagonist (rlepm7.5) was used, was limited to the period of injections and might rather be attributed to the blockage of the interaction of leptin with possible hormonal pathways involved in growth regulation, rather than to toxic effects. The critical role of leptin in developmental programming has been previously reported in ob/ob-deficient mice and intrauterine growth retardated rat pups. In both cases, negative programming that results from either total leptin deficiency or fetal undernutrition have been reversed postnatally by leptin supplementation. 23, 28 However, our study is the first to demonstrate that in a normal animal, independently of an adverse fetal programming or genetic deficiency, leptin disruption during a critical neonatal window is sufficient to alter permanently the long-term metabolic regulation. The current results indicate that the postnatal leptin surge, occurring normally, is crucial to ensure adequate metabolic regulation and that leptin levels may be a limiting factor during the first two weeks of life, at least in rodents, for the onset of a normal food intake regulation. In the newborn, leptin is produced mainly by the adipose tissue but also, by ectopic sources and specifically the stomach. 37 Exogenous leptin is also provided to the neonate via maternal milk as leptin is synthesized and secreted by the mammary gland. 9, 10 Several studies have demonstrated the importance of the contribution of maternal milk to the serum leptin concentrations in the newborn. 38, 39 Indeed, at this stage of development, the immaturity of the gastrointestinal tract of the neonate allows the absorption of leptin in blood stream. This absorbed leptin has been shown to be efficient to control several endocrine processes and thermoregulation. Postnatal leptin blockage promotes obesity L Attig et al Epidemiological studies, supported by recent experimental data in rodent, have already emphasized the importance of maternal milk and the potent role of milk leptin for its protective effects against the development of overweight and obesity with age. [42] [43] [44] Our strategy to inject leptin antagonist in pups has allowed us to block both endogenous and exogenous leptin sources. If maternal leptin brought by the milk appears to be the main source of leptin for the newborn, this would constitute an important parameter to be controlled or improved particularly in pathological cases of leptin deficiency, especially such as those observed in intrauterine growth retardated babies.
In summary, the present results clearly demonstrate the physiological importance of the postnatal leptin surge for the optimal onset of the metabolic regulation, at least in rodents, and its implication in the prevention of deleterious developmental programming. Additional basic research is necessary to a better understanding of the biological mechanisms involved. Experiments are in progress to determine whether leptin disruption in early life resulted primarily in hypothalamic damages, thus promoting the development of central leptin resistance in later life.
